Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion Technologies (ALUR) announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Outset Medical (OM – Research Report) and ...

Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive ...

NATICK, Mass., January 21, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...

The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...